Print this Page Return to Webview
 
 
Infusion Site Management » Disclosure and References

Infusion Site Management Guide


Disclaimer

While every reasonable precaution has been taken in the preparation of this guide, no author, editor, or publisher shall have any responsibility for errors or omissions, nor for the uses made of the materials herein and the decisions based on such use. This document does not contain all the information for proper care and treatment of people who manage their diabetes with an insulin pump. Individuals should check with their physician or diabetes health care team before implementing any changes to their diabetes treatment plan. No warranties are made, expressed, or implied, with regard to the contents of this work or to its applicability to specific patients or circumstances. No author, editor, or publisher shall be liable for direct, indirect, special, incidental or consequential damages arising out of the use or inability to use the contents of this guide.

This guide is not meant to be a substitution for professional medical care. Always consult the health care team for treatment plans and recommendations.

References

  1. Bolderman K RD LD CDE. Putting your patients on the pump. American Diabetes Association; 2002.
  2. Buse J. What should be the frequency of rotation of skin sites for insulin injections? Diabetes & Endocrinology Ask the Expert. Medscape Diabetes and Endocrinology. 3(2): 2001. www.medscape.com/viewarticle/412395.
  3. Eising S, Zass R, Heise T, Koch H, Harms E. Impact of lipohypertrophy on metabolic control in paediatric patients with diabetes mellitus type 1. Diabetologia. 2002; 45(suppl 2): A283.
  4. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Experimental & Clinical Endocrinology and Diabetes. 1996; 104(2): 106-110.
  5. Walsh J, Roberts R. Pumping Insulin. 3rd Edition. Sand Diego, CA: Torrey Pines Press; 2000: 39-41; 211-219.
  6. Wolpert H MD. Editor. Smart Pumping for People with Diabetes. American Diabetes Association; 2003.

Micropore™ , Tegaderm™ , Tegaderm™ HP and Transpore™ are registered trademarks of 3M Company.
Bard® Protective Wipes is a registered trademark of C. R. Bard, Inc. DuoDerm® is a registered trademark of Bristol-Myers Squibb Company or one of its divisions or sub-sidiaries.
Hibiclens® is a registered trademark of Ely Drugs.
Detachol® , LMX™4 cream and Mastisol® (Latex-free) are registered trademarks of Ferndale Laboratories, Inc.
Bactroban Cream® is a registered trademark of GlaxoSmithKline UK. Numby stuff® is a registered trademark of iOMED, Inc.
Aveeno® and Bioclusive™ are registered trademarks of Johnson & Johnson Consumer Companies, Inc. or one of its divisions or subsidiaries.
Paradigm® is a registered trademark of Medtronic MiniMed. Mefix® is a registered trademark of Mölnlycke Health Care™ .
Benadryl® spray, Caladryl® , Neosporin® and Polysporin® are registered trademarks of Pfizer Inc.
Cortizone is a Pfizer Inc. product. Betadine® is a registered trademark of Purdue Pharma L.P.
Hypafix™ , IV Prep® wipes, OpSite®IV 3000, Remove™ , Skin Bond® (Latex based), Skin-Prep® and Uni-Solve® are registered trademarks of Smith & Nephew.
Tincture of Benzoin is a Smith & Nephew product. Skin-Tac-H® (Latex-free) is a registered trademark of Torbot Group, Inc.
PolySkin™ II is a registered trademark of Tyco Healthcare Group LP.

©2005 Disetronic Medical Systems, Inc.

Disetronic Medical Systems, Inc.
11800 Exit 5 Parkway, Ste. 120
Fishers, IN 46037

phone 800-280-7801
fax 888-810-0758
info@disetronic-ca.com
www.disetronic-ca.com